News Headlines

  1. Almac Announces Multi-Million-Pound Investment In Singapore 11/17/2025

    Almac Group has announced a multi-million-pound investment to expand its facility in Singapore, as the company marks ten years of operations in the country.

  2. Merus And Halozyme Enter Global Collaboration And License Agreement To Develop Subcutaneous Formulation Of Petosemtamab 11/17/2025

    Merus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), and Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme"), a leader in subcutaneous drug delivery solutions, today announced they have entered into a global non-exclusive collaboration and license agreement. 

  3. Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences For The Use Of Proprietary Next-Generation Capsid AAV-SLB101 11/17/2025

    Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences (Andelyn), a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.

  4. Polpharma Biologics Confirms U.S. Launch Of Tyruko (natalizumab), The First And Only Biosimilar For Multiple Sclerosis 11/17/2025

    Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko (natalizumab-sztn) is now available to patients in the United States.

  5. Ajinomoto Co., Inc. And Forge Biologics Develops Culture Media Supplements To Improve Productivity Of Gene Therapy Products 11/14/2025

    Ajinomoto Co., Inc. (“Ajinomoto Co.”) has collaborated with its consolidated subsidiary, Forge Biologics (“Forge”), to develop culture media supplements that enables more efficient cultivation of viral vectors*1, a primary delivery technology used in gene therapy products*2 .

  6. Pfizer Completes Acquisition Of Metsera 11/13/2025

    Pfizer Inc. today announced the successful completion of its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.

  7. Lupin Manufacturing Solutions Unveils Dedicated Oncology Block At Vizag, India 11/12/2025

    Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of global pharma major Lupin Limited (Lupin), today announced the commissioning of its dedicated Oncology Block at its Vizag facility in India.

  8. Genezen Announces Manufacturing Partnership With Humane Genomics To Advance Oncolytic Virus Therapy For Pediatric Liver Cancer 11/12/2025

    Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Humane Genomics, a biotechnology company developing oncolytic viral therapies, today announced a partnership for process transfer and cGMP manufacturing of HGI627, a novel therapy targeting pediatric liver cancer (hepatoblastoma).

  9. EirGenix Signed The Commercial Licensing Agreement For Its Second HER2 Biosimilar Asset EG1206A 11/12/2025

    EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosimilar, EG1206A (Pertuzumab Biosimilar to Roche Perjeta®), covering all territories except Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, and Japan. The agreement further strengthens the two companies' collaborative development of the HER2 biosimilar product.

  10. Kytopen And Excellos Explore New Pathways To Non-Viral Cell Therapy Manufacturing 11/12/2025

    Kytopen Corp., a leader in continuous flow cellular engineering, and Excellos, Inc., a cell therapy CDMO and member of Blood Centers of America (BCA), today announced that the two companies are exploring a collaboration to advance non-viral cell therapy manufacturing technologies.